Results 161 to 170 of about 2,565,028 (307)

A comprehensive review on pain: Model, target, therapy, and prospect (Review). [PDF]

Int J Mol Med
Chang C, Wu X, Liu K, Wang L, Adu M, Lin Q, Huang H, Ma Q, Wei R, Wang X, Liu W.   +10 more
europepmc   +1 more source

Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer. [PDF]

Pharmaceutics, 2023
Beljkas M, Ilic A, Cebzan A, Radovic B, Djokovic N, Ruzic D, Nikolic K, Oljacic S.   +7 more
europepmc   +1 more source

Targeted Therapies; Who Detects the Target?

Analytical Cellular Pathology, 2005
G. A. Meijer, J. J. Oudejans
openaire   +3 more sources

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

Molecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel, Peyman Zarrineh, Nathnael T. Tuffa, Jigar H. Sheth, Sumitra Mohan, Mudassar Iqbal, Sankari Nagarajan   +6 more
wiley   +1 more source

PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models. [PDF]

J Exp Clin Cancer Res
Valentini E, Gentile G, Di Martile M, D'Aguanno S, Brignone M, Di Stefano AM, Di Caprio M, Melucci E, Botti C, Pelle F, Ortolano A, Fattore L, Mancini R, Ciliberto G, Rotili D, Del Bufalo D.   +15 more
europepmc   +1 more source

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

Molecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova, Zuzana Kozovska, Ondrej Pos, Kristina Pavlov, Sachin Gulati, Peter Makovicky, Kristina Jakic, Monika Burikova, Eva Sedlackova, Barbora Svitkova, Silvia Tyciakova, Vojtech Bystry, Nicolas Blavet, Boris Tichy, Matej Hrnciar, Jaroslav Budis, Miroslav Tomas, Peter Dubovan, Georgina Kolnikova, Veronika Repaska, Nikoleta Mojzesova, Eva Zomborska, Daniel Pindak, Michal Mego, Tomas Szemes, Miroslava Matuskova   +25 more
wiley   +1 more source

Toward Personalized Response Monitoring in Melanoma Patients Treated with Immunotherapy and Target Therapy. [PDF]

Diagnostics (Basel)
Venturi F, Magnaterra E, Gualandi A, Scotti B, Baraldi C, Alessandrini AM, Veneziano L, Cama EM, Melotti B, Marchese PV, Tassone D, Ribero S, Ardigò M, Dika E.   +13 more
europepmc   +1 more source

Dual hypoxia-responsive supramolecular complex for cancer target therapy. [PDF]

Nat Commun, 2023
Guo JS, Li JJ, Wang ZH, Liu Y, Yue YX, Li HB, Zhao XH, Sun YJ, Ding YH, Ding F, Guo DS, Wang L, Chen Y.   +12 more
europepmc   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

The Evolution of Tumor Microenvironment in Gliomas and Its Implication for Target Therapy. [PDF]

Int J Biol Sci, 2023
Hu Y, Li Z, Zhang Y, Wu Y, Liu Z, Zeng J, Hao Z, Li J, Ren J, Yao M.   +9 more
europepmc   +1 more source